tbuckley/cabot-search huggingface dataset:
HDAC in gastric cancer: Expression patterns and prognostic implications
Authors: Wilko Weichert, Annika Roske, Volker Gekeler, Thomas Beckers, Matthias Ebert, Matthias Pross, Manfred Dietel, Carsten Denkert, Christoph Rocken
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

4096 

Post-translational modifications of core histones by histone deacetylases (HDACs) are known to play an important role in the regulation of genes intimately linked to the initiation and progression of malignant tumors. However, although HDAC inhibitors (HDI) have entered late phase clinical trials for the treatment of a variety of cancers, still little is known on the expression patterns of HDAC isoforms in tumors. In our study we addressed this apparent lack of translational information for gastric cancer.    Two cohorts of 143 (training cohort) and 150 (validation cohort) gastric cancer patients from two single german university hospitals were investigated for the expression of class I HDACs 1, 2 and 3. Isoform expression was correlated with clinico-pathological parameters and patient survival.    Roughly one third (training cohort: 21.7% / validation cohort: 35.3%) of gastric cancers showed none to weak expression of HDAC 1, 2 and 3, another third of tumors highly expressed one or two isoforms (42% / 43.4%) while the remaining third showed strong expression of all three proteins (36.3% / 21.3%). Grouped HDAC expression (gHDAC) in both cohorts was significantly higher in those patients having lymph node metastases (p<0.005). In multivariate analyses, gHDAC expression as well as HDAC2 expression had independent negative prognostic impact in the training (gHDAC: RR=4.2, p=0.025, HDAC2: RR=3.6, p=0.010) and in the validation cohort (gHDAC: RR=2.2, p=0.043, HDAC2: RR=1.7, p=0.022).    In conclusion, the confirmed independent prognostic impact of HDAC isoforms suggests that an evaluation of HDAC expression profiles prior to HDI treatment might help to identify patient populations who will exceptionally benefit from such a treatment. This should be considered when clinical trials for HDI are planned.
Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up.
Authors: Cristina Papayannidis, Anna Candoni, Stefania Paolini, Emanuela Ottaviani, Ilaria Iacobucci, Michela Rondoni, Michele Malagola, Pier Paolo Piccaluga, Renato Fanin, Giuseppe Visani, Michele Baccarani, Domenico Russo, Giovanni Martinelli
Journal: Blood (2008)
The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects.
Authors: Dror Shalitin, Michael Share, Richard A. Campbell, Jeffrey Steinberg, Eric Sanchez, Joseph Wang, Richard Leuchter, Mingjie Li, Cathy S. Wang, Haiming Chen, James R. Berenson
Journal: Blood (2007)
Dissociation of Phospholipids “Flip-Flop” and CD16 Downregulation in Stimulated Neutrophils with FMLP and TNFα in Relationship with ROS Production.
Authors: Brigitte F. Cantinieaux, Véronique Kerrels, Zaïna Kassengera, Marie Guivarch, Christophe Kails, Claudine Kanengele-Mukalay, Francine Ntakibirora
Journal: Blood (2004)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
Authors: L. Paz-Ares, E.-H. Tan, K. O’Byrne, L. Zhang, V. Hirsh, M. Boyer, J.C.-H. Yang, T. Mok, K.H. Lee, S. Lu, Y. Shi, D.H. Lee, J. Laskin, D.-W. Kim, S.A. Laurie, K. Kölbeck, J. Fan, N. Dodd, A. Märten, K. Park
Journal: Annals of Oncology (2017)

In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data.LUX-Lung 7 assessed afatinib 40 mg/day versus gefitinib 250 mg/day in treatment-naïve patients with stage IIIb/IV NSCLC and a common EGFR mutation (exon 19 deletion/L858R). Primary OS analysis was planned after ∼213 OS events and ≥32-month follow-up. OS was analysed by a Cox proportional hazards model, stratified by EGFR mutation type and baseline brain metastases.Two-hundred and twenty-six OS events had occurred at the data cut-off (8 April 2016). After a median follow-up of 42.6 months, median OS (afatinib versus gefitinib) was 27.9 versus 24.5 months [hazard ratio (HR) = 0.86, 95% confidence interval (CI) 0.66‒1.12, P = 0.2580]. Prespecified subgroup analyses showed similar OS trends (afatinib versus gefitinib) in patients with exon 19 deletion (30.7 versus 26.4 months; HR, 0.83, 95% CI 0.58‒1.17, P = 0.2841) and L858R (25.0 versus 21.2 months; HR 0.91, 95% CI 0.62‒1.36, P = 0.6585) mutations. Most patients (afatinib, 72.6%; gefitinib, 76.8%) had at least one subsequent systemic anti-cancer treatment following discontinuation of afatinib/gefitinib; 20 (13.7%) and 23 (15.2%) patients received a third-generation EGFR tyrosine kinase inhibitor. Updated PFS (independent review), TTF and ORR data were significantly improved with afatinib.In LUX-Lung 7, there was no significant difference in OS with afatinib versus gefitinib. Updated PFS (independent review), TTF and ORR data were significantly improved with afatinib.NCT01466660.
Eczema in Younger Childhood Is a Risk Factor for Development of Food Allergy after Liver Transplantation
Authors: Motoko Mitsui, Tetsuo Shoda, Osamu Natsume, Miori Sato, Akio Yoshida, Miyuki Ohta, Yumiko Miyaji, Shinichiro Inagaki, Tatsuki Fukuie, Ichiro Nomura, Masami Narita, Akinari Fukuda, Seisuke Sakamoto, Mureo Kasahara, Yukihiro Ohya
Journal: Journal of Allergy and Clinical Immunology (2017)
Foxo 3a Signaling Mediates Apoptosis in Lymphoma Cells By the Diterpenoid Lactone Andrographolide (Andro), the Active Component of Andrographis Paniculata
Authors: Shuo Yang, Bo Ding, Fei Ying, Jana Svetlichnaya, Austin Tom, Sheila Prachand, Yanzhuang Wang, Leo I Gordon
Journal: Blood (2015)
CCR4: TARC Interaction Provides Supplementary Pro-Survival and Proliferative Signals to Chronic Lymphocytic Leukemia Cells.
Authors: Rajendra N Damle, Sonal Temburni, Matthew Kaufman, Jonathan E. Kolitz, Steven L. Allen, Fabio Malavasi, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2009)
Autologous Bone-Marrow Stem Cell Support in Acute Anterior Myocardial Infarction.
Authors: Daniele Vallisa, Massimo Piepoli, Luigi Cavanna, Cristina Arbasi, Carlo Moroni, Antonio Lazzaro, Alessandro Capucci, Patrizia Bernuzzi, AnnaLisa Arcari, Costanza Bosi
Journal: Blood (2007)
IMST-05. NOVEL CAR-T CELLS TARGETING THE EXTRACELLULAR MATRIX OF GLIOBLASTOMA INDUCE STRONG ANTI-TUMOR IMMUNE RESPONSE
Authors: Sadhak Sengupta, Nandhu Mohan, E. Antonio Chiocca, Prakash Sampath, Mariano Viapiano
Journal: Neuro-Oncology (2016)

To address the poor prognosis and dismal survival of glioblastoma (GBM) patients, immunotherapy is increasingly being considered as a fourth arm of treatment in addition to surgical resection, radiotherapy, and adjuvant chemotherapy with temozolomide. Adoptive tumor immunotherapies using engineered T cells expressing chimeric antigen receptors (CAR-T cells) targeting cell surface antigens have shown promising outcomes in hematological malignancies. Although several CAR-T cell-based approaches have been tested in GBM, it has been difficult to translate the success of CAR-T cell therapy observed in liquid malignancies. Here we discuss the development of a first-in-kind CAR-T cell that does not target an antigen on the tumor cell surface but in the tumor extracellular matrix (ECM), specifically, the ECM protein fibulin-3 that is expressed by GBM tumor cells but is absent in the brain. In vitro experiments demonstrated that anti-fibulin-3 CAR-T cells (Fib3 CAR-T) are immunologically reactive to fibulin-3-expressing GBM tumor cells as evidenced by: 1) increased CAR-T cell proliferation; 2) overexpression of IFN-gamma, IL-2, perforin, and granzyme; and 3) enhanced cytotoxicity to the tumor cells. Control experiments using fibulin-3-lacking cells yielded no such results. Treatment of animals implanted with fibulin-3-expressing GBM xenografts, using intratumoral fib3 CAR-T injections, resulted in statistically significant increase in median survival compared to animals treated with untransduced or non-specific T cells. Fib3 CAR-T is the first CAR-T developed to recognize a non-cell-surface target/antigen and raises interesting possibilities of novel immunotherapeutic targets in the tumor ECM. Fib3 CAR-T can help overcome a major deterrent for the success of CAR-T therapy that results from the reduced exposure of these engineered T cells to cell surface target/antigens in solid tumors like GBM.
An Important Step Forward for Biosimilars in Cancer Treatment
Authors: Stephen M. Schleicher, Andrew D. Seidman
Journal: JAMA Oncology (2017)

This commentary discusses the findings of a randomized clinical trial of trastuzumab vs a biosimilar in patients with metastatic breast cancer that was published in JAMA and posits 3 questions for consideration moving forward in the development and clinical use of biosimilars.
Bone Marrow Stroma Protects BCR-ABL-Negative Myeloproliferative Neoplasms from Ruxolitinib- and Vorinostat-Induced Apoptosis
Authors: Bruno A Cardoso, Helio Belo, Ana Isabel Oliveira, Olga Pereira, Joao T Barata, Antonio Almeida
Journal: Blood (2014)
Homeobox NKX2-3 Is Over-Expressed in Human B-Cell Lymphomas and Drives Marginal Zone B-Cell Lymphomagenesis in Mice
Authors: Eloy F Robles, Beatriz Aldaz, Takashi Akasaka, Laura Macri Pellizzeri, Eduardo Martinez-Anso, Xavier Aguirre, Felipe Prosper, Idoia Martin-Guerrero, Victor Segura, Maria José Calasanz, Isidro Sanchez-Garcia, Elena Campos-Sanchez, Cesar Cobaleda, Charlotte Cresson, Cyril Broccardo, Reiner Siebert, Xabier Sagaert, Martin JS Dyer, Jose A Martinez-Climent
Journal: Blood (2011)
Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
Authors: C. Hessel, M. Mangeshkar, R.J. Motzer, B. Escudier, T.B. Powles, G. Schwab, T.K. Choueiri
Journal: Annals of Oncology (2016)
Does BCG have non-specific effects on childhood mortality?
Authors: Lone G Stensballe
Journal: BMJ (2017)

Higgins and colleagues mention that BCG can reduce childhood mortality more than would be expected from its specific protection against tuberculosis alone.1 In 2011, a trial in Guinea-Bissau among infants with low birth weight found that BCG was associated with lower neonatal mortality.2

In 2012-15 we tested whether BCG had …
Annals Story Slam - The Professor and the Pap Smear
Authors: Katherine Sherif
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - The Professor and the Pap SmearFREEKatherine Sherif, MDKatherine Sherif, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0019 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - The Professor and the Pap Smear "The Professor and the Pap Smear," by Katherine Sherif, MD (Duration 4:41)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Katherine Sherif, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, Katherine.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Hodgkin Variant of Richter's Syndrome: Report of 34 Cases. A Role of EBV in Transformation.
Authors: Bénédicte Deau, Caroline Bonmati, Emmanuel Bachy, Xavier Carles, Pauline Brice, Franck Morschhauser, Philippe Rousselot, Marie-Olivia Chandesris, Richard Delarue, Bruno Varet, Vincent Ribrag, Olivier Hermine
Journal: Blood (2009)
LBA2 Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer receiving myelotoxic chemotherapy: Pooled subgroup analysis of two randomized trials
Authors: N. Harbeck, P. Gascon, C.M. Jones, A. Nixon, A. Krendyukov, R. Nakov, M. Mo, K.L. Blackwell
Journal: Annals of Oncology (2016)
Statistical controversies in clinical research: futility analyses in oncology–lessons on potential pitfalls from a randomized controlled trial
Authors: E. Lesaffre, M.J. Edelman, N.H. Hanna, K. Park, N. Thatcher, S. Willemsen, B. Gaschler-Markefski, R. Kaiser, C. Manegold
Journal: Annals of Oncology (2017)
Remission of Paroxysmal Atrial Fibrillation with Iron Reduction in Hemophilia A.
Authors: Leo R. Zacharski, Laurel J McKernan, Michael E Metzger, Maura G Malone, Vivek Samnotra, Archana Bhargava, Paul R Steiner, Cocav Rauwerdink, Deborah L Ornstein, Cornelius J. Cornell
Journal: Blood (2009)
Rehabilitation strategies following oesophageal cancer: The ReStOre trial—A feasibility study.
Authors: Emer M. Guinan, Suzanne Doyle, Linda O'Neill, Jacintha O'Sullivan, Prof John V Reynolds, Juliette M. Hussey
Journal: Journal of Clinical Oncology (2016)

176 Background: Esophageal cancer is an examplar model of complex cancer care with defined quality of life (QOL) consequences. While prognosis for this aggressive disease is poor, survival is slowly improving leading to the emergence of a unique group of cancer survivors with complex rehabilitation needs. The ReStOre trial will implement a multi-disciplinary programme to improve functional performance and QOL for esophageal cancer survivors. This pilot work examines the feasibility of the proposed intervention. Methods: This study was a single-arm feasibility study. Patients who had completed curative treatment for esophageal cancer including esophagectomy and who had node-negative post-surgical pathology received a letter of invitation to participate. The programme consisted of 12 weeks supervised and home-based exercise, dietetic counselling and education sessions from the multi-disciplinary team. Feasibility outcomes included recruitment rates, adherence, adverse events and retention. Other outcomes, including cardiopulmonary fitness (maximal cardiopulmonary exercise test and six minute walk test (6MWT)), QOL (EORTC questionnaire) and body composition (bioimpedence analysis), were assessed pre- and post-intervention. Results: Twelve participants (mean (standard deviation (SD) age 61.4 (7.29) years, 8 male) consented to participate, representing a recruitment rate of 55%. Mean class attendance was 82% and mean adherence to the home exercise programme was 118%. No adverse events occurred and all participants completed programme. Aerobic fitness improved by 3.71(2.7) ml/kg/min (19.0 ml/kg/min pre-intervention, 22.7 ml/kg/min post-intervention, p &lt; 0.001). 6MWT distance improved by 56.3 (35.3)m (p &lt; 0.001). Global and functional QOL scores increased while symptom scores decreased. Body composition remained stable. Conclusions: The ReStOre trial demonstrated high feasibility and acceptability in this complex cohort. Improvements in functional performance and QOL were evident without compromise to body composition. While current results are limited due to the selected population and single-arm design they will guide the design of the forthcoming larger randomised controlled trial.
Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy.
Authors: Richard Schlenk, Kristina Sohlbach, Marie-Luise Hütter, Patrice Ceballos, Nathalie Fegueux, Emmanuel Raffoux, Herve Dombret, Mike Dennis, Jo Tomlins, Jette Tjørnelund, Andreas Neubauer
Journal: Blood (2008)
Dental and Maxillofacial Alterations in Children with Allergic Rhinitis Attended at the University Hospital of Monterrey, Mexico
Authors: Rosa Ivett Guzman-Avilan, Sandra N. González Diaz, Alfredo Arias Cruz, Alejandra Macias-Weinmann, Gabriela Galindo Rodriguez, Claudia Gallego Corella, Barbara Elizondo Villarreal, Katia Guzman Avilan, Cindy Elizabeth de Lira-Quezada
Journal: Journal of Allergy and Clinical Immunology (2017)
Heme-Mediated Change in Sensitivity to Anti-Leukemia Reagents in BCR/ABL-Positive Cell Lines.
Authors: Ken Ohmine, Tadashi Nagai, Satoru Kikuchi, Takuji Miyoshi, Makiko Nakamura, Takahito Kondo, Norio Komatsu, Kazumichi Furuyama, Keiya Ozawa
Journal: Blood (2005)
NTOX-10. RETROSPECTIVE REVIEW OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES FROM A SINGLE CANCER CENTER DIAGNOSED WITH PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
Authors: Elizabeth Neil, Marc Rosenblum
Journal: Neuro-Oncology (2016)

PML is an uncommon opportunistic infection that causes considerable morbidity and mortality. IRB-approved retrospective review of medical records identified by diagnostic coding for PML or JC virus (JCV) from 2000-2015. Inclusion criterion was cerebrospinal fluid (CSF) positive for JCV by PCR or brain biopsy proven PML. Of the 23 patients identified, we excluded five with HIV and two with false positive CSF results for a total of sixteen. Twelve(75%) were men. Median age was 56(31-71) with 7(44%) older than age 60. Five(31%) had CLL, 3(19%) AML, 3(19%) mantle cell lymphoma, and one patient each with ALL, Hodgkin lymphoma, myeloma, Waldenstrom macroglobulinemia, or B-cell lymphoma NOS. One patient with CLL was untreated. Of the remaining 15 patients, all received conventional chemotherapy, 9(60%) underwent transplant (7 were allogeneic), 2(13%) total body irradiation, and 13(87%) had immunomodulating therapy. Nine of these 13 patients received rituximab with 8(89%) receiving >6 months of treatment. Median time from cancer diagnosis to PML was 48.5 months with the diagnosis of PML confirmed a median of 2.1 months from neurological symptom onset. However, the median time to PML diagnosis was 5.4 months for four patients presenting with a cerebellar ­syndrome. Four(22%) had negative CSF testing, but a diagnostic brain biopsy. Ten(63%) received PML-directed treatment; most commonly cidofivor in 4(25%) patients, mefloquine 3(19%), mirtazapine 3(19%). Median survival from PML diagnosis for patients on treatment was 4.6 months and without was 0.9 months. In our series, 22% had negative CSF testing, but a diagnostic brain biopsy. The patient without cancer-directed therapy exemplifies the innate immunosuppressive nature of hematologic malignancies. Median survival may have been longer with PML-directed treatment because these patients appeared to be less debilitated. Finally, while exceedingly rare, PML may present as a cerebellar syndrome which was unrecognized as PML and delayed the diagnosis.
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
Authors: Brigitte Dréno, Rainer Kunstfeld, Axel Hauschild, Scott Fosko, David Zloty, Bruno Labeille, Jean-Jacques Grob, Susana Puig, Frank Gilberg, Daniel Bergström, Damian R Page, Gary Rogers, Dirk Schadendorf
Journal: The Lancet Oncology (2017)
P01.10 Effects of valproic acid on NF-κB signaling in glioblastoma
Authors: S. Berendsen, E. Frijlink, J. Kroonen, W. G. M. Spliet, W. Van Hecke, T. Seute, T. J. Snijders, P. A. Robe
Journal: Neuro-Oncology (2016)

Despite high expression of the angiogenic stimulator VEGF-A and recently reported autocrine VEGF-A-
Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
Authors: P. Bono, C. Massard, K. Peltola, A. Azaro, A. Italiano, R.S. Kristeleit, U.N. Lassen, H.-T. Arkenau, P. Hakulinen, C. Garratt, T. Ikonen, M. Mustonen, J. Rodon
Journal: Annals of Oncology (2018)
IL10 Genetic Variants Are Associated With House Dust Mite-Allergy But Not Directly On Asthma In A Severe Asthma Case-Control Study
Authors: Héllen Freitas Fonseca, Ryan Santos Costa, Tamires Cana Brasil Carneiro, Regina Santos Nascimento, Gerson Almeida Queiroz, Anaque Oliveira Pires, Alvaro Augusto Cruz Filho, Camila Alexandrina Figueiredo
Journal: Journal of Allergy and Clinical Immunology (2017)
Single or dual antiplatelet therapy after PCI
Authors: Yosuke Miyazaki, Pannipa Suwannasom, Yohei Sotomi, Mohammad Abdelghani, Karthik Tummala, Yuki Katagiri, Taku Asano, Erhan Tenekecioglu, Yaping Zeng, Rafael Cavalcante, Carlos Collet, Yoshinobu Onuma, Patrick W. Serruys
Journal: Nature Reviews Cardiology (2017)
Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study
Authors: Richard E. Clark, Fotios Polydoros, Jane F. Apperley, Christopher Pocock, Graeme Smith, Jenny L Byrne, Stephen G. O'Brien, Tony Coffey, Letizia Foroni, Mhairi Copland
Journal: Blood (2016)
The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia
Authors: Ya-Zhen Qin, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Wei Han, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yao Chen, Xiao-Dong Mo, Xiao-Su Zhao, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang
Journal: Journal of Hematology & Oncology (2017)

The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t(8;21) acute myeloid leukemia (AML). RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation (1530 samples in total). A total of 92.3% of the requested samples were collected, and 74.0% of patients had complete sample collection. The 1-, 3-, and 6-month RUNX1-RUNX1T1 transcript levels could significantly discriminate between continuous complete remission and a hematologic relapse at 1.5–3, 4–6, and 7–12 months but not at >3, >6, and >12 months, respectively. Over 90% of the 175 patients who were in continuous complete remission had a ≥3-log reduction in RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a ≥4-log reduction at ≥12 months. A <3-log reduction within 12 months and/or a <4-log reduction at ≥12 months was significantly related to a higher 3-year cumulative incidence of relapse (CIR) rate in both the entire cohort and the patients with no intervention after HSCT (58.4 vs. 2.2%, 76.5 vs. 2.0%; all P < 0.0001). Patients who had received a preemptive donor lymphocyte infusion when the increase in RUNX1-RUNX1T1 transcripts was ≤1-log according to the above dual cutoff values had significantly lower 1-year CIR rate after intervention than the patients who had received an infusion when the increase was >1-log (0 vs. 55.0%, P = 0.015). RUNX1-RUNX1T1 transcripts with a <3-log reduction from diagnosis within 12 months and/or a <4-log reduction at ≥12 months after allo-HSCT could accurately predict relapse and may prompt a timely intervention in patients with t(8;21) AML.
Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas
Authors: Pablo L Ortiz-Romero, Gonzalo Gomez-Lopez, Sagrario Gómez de Benito, Veronica Monsalvez, Jose P Vaque, Nerea Martinez, Ignacio Varela, Osvaldo Grana, Socorro M Rodríguez-Pinilla, Jose L. Rodriguez-Peralto, Miriam Rubio-Camarillo, Esperanza Martin, Miriam Mendez, Jose A Garcia-Marco, Mariano Provencio, Gaston Roustan, Mercedes Hospital, Lola Suarez, Orlando Dominguez, Miguel A. Piris, Margarita Sanchez-Beato
Journal: Blood (2012)